General Toxicity Evaluation of Cardiovascular Drugs

General toxicity evaluation is an important part in preclinical toxicity studies of cardiovascular drugs. Ace Therapeutics can provide clients with a full range of preclinical general toxicity evaluation of cardiovascular drugs, including acute toxicity evaluation, sub-chronic toxicity evaluation, and chronic toxicity evaluation.

Overview of General Toxicity Evaluation of Cardiovascular Drugs

As we know, general toxicity evaluation is the most basic and critical part of preclinical toxicity studies. For cardiovascular drugs, the main purpose of preclinical general toxicity evaluation is to clarify the target organ toxicity, dose-dependent toxicity, and the reversibility of toxicity for experimental animals. The results of general toxicity evaluations may guide drug dosage references for subsequent toxicity evaluations of cardiovascular drugs.

Fig. 1 Reversal activity and toxicity of heparin-binding copolymer after subcutaneous administration of enoxaparin in mice. (Swieton J, et al., 2024)

Ace Therapeutics can provide professional preclinical general toxicity evaluation of cardiovascular drugs to support drug development for cardiovascular diseases.

Available Experimental Animals

Depending on the mechanism of cardiovascular drugs, we can provide different experimental animal species for general toxicity evaluation of cardiovascular drugs.

Acute Toxicity Evaluation

We can obtain the following toxicological parameters by administering single or multiple doses to experimental animals within 24 hours.

Sub-chronic/Chronic Toxicity Evaluation

Sub-chronic toxicity evaluation is the focus of general toxicity studies. We can assess the toxic response and target organ toxicity in experimental animals after repeated administration of the drug through sub-chronic toxicity studies. In addition, if the cardiovascular drug is to be used for a long period of time, we can also conduct chronic toxicity studies for a period of 6 months to 2 years. Here are some parameters for sub-chronic/chronic toxicity assessment.

Ace Therapeutics is a contract research organization specializing in research services for cardiovascular drugs. With our specialized research team and rich research experience in the field of cardiovascular drug toxicity evaluation, we can provide preclinical general toxicity evaluation services for cardiovascular drugs. If you are interested in our services, please don't hesitate to contact us.

1. Swieton, J.; et al. Reversal activity and toxicity of heparin-binding copolymer after subcutaneous administration of enoxaparin in mice. Int J Mol Sci. 2021, 22(20):11149.